| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 12/16/2009 | EP2132203A1 Thiazolyl compounds useful as kinase inhibitors |
| 12/16/2009 | EP2132200A2 Nitro-imidazole hypoxia imaging agents |
| 12/16/2009 | EP2132199A1 Substituted pyrimidines |
| 12/16/2009 | EP2132198A1 Solid forms of a raf kinase inhibitor |
| 12/16/2009 | EP2132197A2 Substituted pyrimidines as adenosine receptor antagonists |
| 12/16/2009 | EP2132193A1 Substituted pyrrolidine amides, the production thereof, and the use thereof as medications |
| 12/16/2009 | EP2132191A2 Method for manufacturing neuraminic acid derivatives |
| 12/16/2009 | EP2132189A1 Salts of a selective beta-2 andrenoceptor agonist |
| 12/16/2009 | EP2132187A2 Dual-acting antihypertensive agents |
| 12/16/2009 | EP2132185A2 Pyrimidinyl-piperazines useful as dopamine d3/d2 receptor ligands |
| 12/16/2009 | EP2132182A2 Amorphous solid composition containing a pyrazole-3-carboxamide in amorphous form and stabilising carriers |
| 12/16/2009 | EP2132180A1 Methods and compositions for selectin inhibition |
| 12/16/2009 | EP2132177A1 Pim kinase inhibitors and methods of their use |
| 12/16/2009 | EP2132176A1 4-piperidinylurea compounds as soluble epoxide hydrolase inhibitors |
| 12/16/2009 | EP2132175A2 Process for the preparation of loperamide |
| 12/16/2009 | EP2132174A1 Meta-substituted phenyl sulfonyl amides of secondary amino acid amides, the production thereof, and use thereof as matriptase inhibitors |
| 12/16/2009 | EP2132173A1 Formulations for cathepsin k inhibitors |
| 12/16/2009 | EP2132172A1 Methods of separation and detection of bazedoxifene acetate in pharmaceutical compositions |
| 12/16/2009 | EP2132169A1 New methylenebisphenyl compounds useful in the treatment of inflammation |
| 12/16/2009 | EP2131862A1 A method for non-therapeutic or therapeutic photodynamic skin treatment |
| 12/16/2009 | EP2131858A2 P38 inhibitors |
| 12/16/2009 | EP2131854A1 Use of lhrh antagonists for the treatment of lower urinary tract symptoms, in particular overactive bladder and/or detrusor overactivity |
| 12/16/2009 | EP2131853A1 Methods and compounds for modulating inflammatory processes |
| 12/16/2009 | EP2131849A1 Compositions and methods for delivery of anti-cancer agents |
| 12/16/2009 | EP2131848A2 Compositions and methods for potentiated activity of biologicaly active molecules |
| 12/16/2009 | EP2131846A1 Novel dosage form |
| 12/16/2009 | EP2131845A1 Acid addition salts, hydrates and polymorphs of 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide and formulations comprising these forms |
| 12/16/2009 | EP2131844A1 PTERIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS |
| 12/16/2009 | EP2131843A2 Process for the synthesis of glyt-1 inhibitors |
| 12/16/2009 | EP2131842A2 Use of a compound antagonist to the nk-2-receptors of a neurokinine for the preparation of drugs useful for preventing and treating sexual dysfunction |
| 12/16/2009 | EP2131841A1 Methods for treating acute and subchronic pain |
| 12/16/2009 | EP2131839A2 Compositions comprising derivatives of 3-phenylpyridazine for treating seizure-related disorders |
| 12/16/2009 | EP2131838A1 A medicament for treating schizophrenia comprising cilostazol |
| 12/16/2009 | EP2131837A1 Methods for treating cognitive disorders using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds |
| 12/16/2009 | EP2131836A1 Combination of imidazo ý1,5-a¨pyrazinyl derivatives with an agent that inhibits serine phosphorylation of irs1 for use in the treatment of cancer |
| 12/16/2009 | EP2131833A2 Use of resolvins for inhibition of bone loss |
| 12/16/2009 | EP2131831A1 Conjugated fatty acids and poly-l-lysine for combating pathogenic micro-organisms |
| 12/16/2009 | EP2131830A2 Pharmaceutical form with impeded abuse |
| 12/16/2009 | EP2131829A1 Ppar-gamma agonists for the induction of cationic antimicrobial peptide expression as immunoprotective stimulants |
| 12/16/2009 | EP2131827A2 Methods and compositions for treating thalamocortical dysrhythmia |
| 12/16/2009 | EP2131826A2 17beta-hydroxysteroid-dehydrogenase type 1 inhibitors for the treatment of hormone-dependent diseases |
| 12/16/2009 | EP2131825A1 Mineralcorticoid receptor antagonists for the treatment of endometriosis |
| 12/16/2009 | EP2131824A1 Fast-dissolving/disintegrating film preparation having high proportion of active |
| 12/16/2009 | EP2131823A2 Rapid-disintegration monolayer film for the oral administration of active substances |
| 12/16/2009 | EP2131821A1 Nanoparticle comprising rapamycin and albumin as anticancer agent |
| 12/16/2009 | EP2131818A2 Novel dosage form |
| 12/16/2009 | EP2131817A2 Pharmaceutical composition of quetiapine fumarate |
| 12/16/2009 | EP2131809A2 Methods and compositions for normalizing meibomian gland secretions |
| 12/16/2009 | EP2131662A1 Process of producing tomato paste |
| 12/16/2009 | EP2131657A1 Substituted benzodiazepinones, benzoxazepinones and benzothiazepinones as sodium channel blockers |
| 12/16/2009 | EP2131656A2 Phthalazine derivatives |
| 12/16/2009 | EP2131655A2 Tri-aryl/heteroaromatic cannabinoids and use thereof |
| 12/16/2009 | EP2131654A1 Bipyridine carboxamide orexin receptor antagonists |
| 12/16/2009 | EP1940381B1 Ophthalmic pharmaceutical compositions based on amino acids and sodium hyaluronate |
| 12/16/2009 | EP1912644B1 N-(arylalkyl)-1h-pyrrolopyridine-2-carboxamide derivatives, preparation and use thereof |
| 12/16/2009 | EP1904057B1 Hydroquinone ansamycins in the treatment of gastrointestinal stromal tumors |
| 12/16/2009 | EP1888567B1 Heteroaryl-carboxylic acid (sulfamoyl alkyl) amide - derivatives as factor xa inhibitors |
| 12/16/2009 | EP1846355B1 Fatty acid-benzenediol derivatives and methods of making and using thereof |
| 12/16/2009 | EP1830848B1 Use of thiazolidinone derivatives for the treatment of solid tumors |
| 12/16/2009 | EP1805165B1 1-(hetero)aryl-3-amino-pyrrolidine derivatives for use as mglur3 receptor antagonists |
| 12/16/2009 | EP1778684B1 4-PIPERAZINYL-PYRIMIDINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D<sb>3</sb> RECEPTOR |
| 12/16/2009 | EP1765272B1 Method of decreasing sebum production and pore size |
| 12/16/2009 | EP1729770B1 Sns-595 and methods of using the same |
| 12/16/2009 | EP1660074B1 7-carboxymethyloxy-3 , 4 , 5-trimethoxy flavone monohyd rate, the preparation method and uses thereof |
| 12/16/2009 | EP1619180B1 CaSR ANTAGONIST |
| 12/16/2009 | EP1592407B1 Sustained release device and method for ocular delivery of carbonic anhydrase inhibitors |
| 12/16/2009 | EP1576159B9 The gene cluster involved in safracin biosynthesis and its uses for genetic engineering |
| 12/16/2009 | EP1521832B1 Anti-fragilis antibody and uses thereof |
| 12/16/2009 | EP1451194B2 Preparation of levofloxacin hemihydrate |
| 12/16/2009 | EP1434603B1 Method of treatment using ligand-immunogen conjugates |
| 12/16/2009 | EP1425028B1 Use of il-18 inhibitors for the treatement or prevention of sepsis |
| 12/16/2009 | EP1390029B1 Phenylindoles for the treatment of hiv |
| 12/16/2009 | EP1322634B1 N-phenyl-2-pyrimidine-amine derivatives |
| 12/16/2009 | EP0848704B2 Form iii crystalline ¬r-(r*,r*) -2-(4-fluorophenyl)-beta-delta-dihydroxy-5-(1-methyl-ethyl)-3-phenyl-4-¬(phenylamino)carbonyl -1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin) |
| 12/16/2009 | EP0824541B1 Nucleic acid ligand complexes |
| 12/16/2009 | CN101606061A Methods and compositions for detecting receptor ligand mimetics |
| 12/16/2009 | CN101605905A Method for glycosylation of flavonoid |
| 12/16/2009 | CN101605893A Novel method of protecting islet cells from apoptosis during the donor harvesting process |
| 12/16/2009 | CN101605892A Rna interference mediated inhibition of map kinase genes |
| 12/16/2009 | CN101605817A Cellulose derivative and method for production thereof |
| 12/16/2009 | CN101605811A Treatment of cachexia |
| 12/16/2009 | CN101605798A Imidazothiazole derivatives |
| 12/16/2009 | CN101605797A Thienopyrimidinones for treatment of inflammatory disorders and cancers |
| 12/16/2009 | CN101605795A Tricyclic compound and medical use thereof |
| 12/16/2009 | CN101605794A Aza-benzofuranyl compounds and methods of use |
| 12/16/2009 | CN101605793A Azabicycloalkane derivatives, preparation thereof and use thereof in therapy |
| 12/16/2009 | CN101605792A Aza-isoindolones and their use as metabotropic glutamate receptor potentiators - 613 |
| 12/16/2009 | CN101605791A 6-benzyl-2,3,4,7-tetrahydro-indolo [2, 3-c] quinoline compounds useful as pde5 inhibitors |
| 12/16/2009 | CN101605790A New aminopyrrolo[1,2-a]indole et aminopyridazino[1,6-a]indole derivatives, method for preparing the same and pharmaceutical compositions containing the same |
| 12/16/2009 | CN101605789A Indolizineacetic acids and their therapeutic use as ligands of the crth2 receptor |
| 12/16/2009 | CN101605788A Substituted diazepine sulfonamides as bombesin receptor subtype-3 modulators |
| 12/16/2009 | CN101605787A Compounds modulating c-fms and/or c-kit activity and uses therefor |
| 12/16/2009 | CN101605786A Imidazopyridine inhibitors of iap |
| 12/16/2009 | CN101605784A Aza-bridged-ring compound |
| 12/16/2009 | CN101605783A New N, N'- 2,4-dianilinopyrimidine derivatives, preparation thereof as drugs, pharmaceutical compositions essentially as ikk inhibitors |
| 12/16/2009 | CN101605782A 2-anilino-4-heteroaryl pyrimidine derivatives, and preparation thereof as medicaments, pharmaceutical compositions, and in particular IKK inhibitors |
| 12/16/2009 | CN101605781A Aryl carboxylic acid cyclohexyl amide derivatives |
| 12/16/2009 | CN101605780A New 2, 4-dianilinopyrimidines, preparation thereof as drugs,pharmaceutical compositions and use thereof essentially as IKK inhibitors |
| 12/16/2009 | CN101605779A Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors |
| 12/16/2009 | CN101605776A 4-imidazolyl-1,2,3,4-tetrahydroquinoline derivatives and their use as aldosterone/11-beta-hydroxylase inhibitors |